Darovasertib Plus Crizotinib in First-Line Metastatic Uveal Melanoma: Phase 1/2 OptimUM-01 Results

The presentation highlights results from the OptimUM-01 study evaluating darovasertib + crizotinib as first-line treatment for metastatic uveal melanoma, showing improved median overall survival (21.1 months) and higher response rates compared with historical standard therapies. The combination demonstrated a manageable safety profile, supporting its continued evaluation in the ongoing registrational OptimUM-02 trial.

Related Content:

Rapid Readouts

MonarchE: Primary Overall Survival Results Of Adjuvant Abemaciclib Plus Endocrine Therapy For HR+, HER2-, High-Risk Early Breast Cancer

Final Analysis of Lenvatinib + Pembrolizumab vs Sunitinib in Patients With Advanced Renal Cell Carcinoma With or Without Bone Metastases in CLEAR

Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer: Five-Year and Post-(Neo)Adjuvant Outcomes From KEYNOTE-775 and LEAP-001